文献速递肾癌与肾肿瘤

肾细胞癌辅助VEGFR靶向治疗:系统综述与汇总分析

Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
PubMed 文献 · Eur Urol · 2018-05-18

该系统综述与汇总分析评估了辅助VEGFR靶向治疗在已手术切除的局限性肾细胞癌中的疗效与安全性。汇总三项随机对照III期试验显示,辅助治疗未显著改善无病生存期(HR 0.92,95%CI 0.82-1.03,p=0.16)或总生存期(HR 0.98,95%CI 0.84-1.15,p=0.84),但3-4级不良事件风险显著增加(OR 5.89,95%CI 4.85-7.15,p<0.001)。探索性分析提示足剂量方案可能改善DFS(HR 0.83,95%CI 0.73-0.95,p=0.005)。

要点

  • 辅助VEGFR靶向治疗未显著改善局限性肾细胞癌患者的DFS或OS。
  • 辅助治疗组3-4级不良事件风险显著升高(OR 5.89)。
  • 足剂量方案可能改善DFS,但需进一步研究确认。

核心结论

  • 汇总分析未显示辅助VEGFR靶向治疗在完全切除的中/高危局限或区域肾细胞癌中显著改善DFS或OS。
  • 足剂量方案可能更可能改善DFS,但需等待进一步结果。
  • 辅助治疗与高级别不良事件相关。

研究设计与样本

  • 系统综述与汇总分析,检索PubMed/Medline、Embase和Cochrane Library(2018年1月),遵循PRISMA声明。
  • 纳入三项随机对照III期试验:ASSURE(n=1943)、S-TRAC(n=615)、PROTECT(n=1135)。

主要发现

  • 辅助VEGFR靶向治疗与对照组相比,DFS无显著改善(HRrandom 0.92,95%CI 0.82-1.03,p=0.16)。
  • OS无显著改善(HRrandom 0.98,95%CI 0.84-1.15,p=0.84)。
  • 3-4级不良事件风险显著增高(ORrandom 5.89,95%CI 4.85-7.15,p<0.001)。
  • 探索性分析中,足剂量起始患者DFS改善(HRrandom 0.83,95%CI 0.73-0.95,p=0.005)。
  • NNT范围从10(S-TRAC)到137(ASSURE)。

关键数值与推荐

  • 三项随机对照III期试验比较:舒尼替尼 vs 安慰剂或索拉非尼 vs 安慰剂(ASSURE,n=1943)、舒尼替尼 vs 安慰剂(S-TRAC,n=615)、帕唑帕尼 vs 安慰剂(PROTECT,n=1135)。

临床怎么用

  • 不推荐常规使用辅助VEGFR靶向治疗用于完全切除的局限或区域肾细胞癌。
  • 足剂量方案可能考虑用于特定患者,但需进一步证据。
  • 需权衡高级别不良事件风险。

局限性

  • 探索性分析结果需进一步验证。
  • 汇总分析基于已发表的随机试验,可能存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Contradictory data exist with regard to adjuvant vascular endothelial growth factor receptor (VEGFR)-targeted therapy in surgically managed patients for localized renal cell carcinoma (RCC). OBJECTIVE: To systematically evaluate the current evidence regarding the therapeutic benefit (disease-free survival [DFS] and overall survival [OS]) and grade 3-4 adverse events (AEs) for adjuvant VEGFR-targeted therapy for resected localized RCC. EVIDENCE ACQUISITION: A critical review of PubMed/Medline, Embase, and the Cochrane Library in January 2018 according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement was performed. We identified reports and reviewed them according to the Consolidated Standards of Reporting Trials and Standards for the Reporting of Diagnostic Accuracy Studies criteria. Of eight full-text articles that were eligible for inclusion, five studies (two of five were updated analyses) were retained in the final synthesis. Study characteristics were abstracted and the number needed to treat (NNT) per trial was estimated. EVIDENCE SYNTHESIS: The three randomized controlled phase III trials included the following comparisons: sunitinib versus placebo or sorafenib versus placebo (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma [ASSURE] study, n=1943), sunitinib versus placebo (S-TRAC, n=615), and pazopanib versus placebo (Pazopanib As Adjuvant Therapy in Localized/Locally Advanced RCC After Nephrectomy study, n=1135). The NNT ranged from 10 (S-TRAC) to 137 (ASSURE study). The pooled analysis showed that VEGFR-targeted therapy was not statistically significantly associated with improved DFS (hazard ratio [HRrandom]: 0.92, 95% confidence interval [CI]: 0.82-1.03, p=0.16) or OS (HRrandom: 0.98, 95% CI: 0.84-1.15, p=0.84) compared with the control group. The adjuvant therapy group experienced significantly higher odds of grade 3-4 AEs (ORrandom: 5.89, 95% CI: 4.85-7.15, p<0.001). In exploratory analyses focusing on patients who started on the full-dose regimen, DFS was improved in patients who received adjuvant therapy (HRrandom: 0.83, 95% CI: 0.73-0.95, p=0.005). CONCLUSIONS: This pooled analysis of reported randomized trials did not reveal a statistically significant effect between adjuvant VEGFR-targeted therapy and improved DFS or OS in patients with intermediate/high-risk local or regional fully resected RCC. Improvement in DFS may be more likely with the use of full-dose regimens, pending further results. However, adjuvant treatment was associated with high-grade AEs. PATIENT SUMMARY: Vascular endothelial growth factor receptor-targeted therapy after nephrectomy for localized kidney cancer is not associated with consistent improvements in delaying cancer recurrence or prolonging life and comes at the expense of potentially significant side effects.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Sun M, Marconi L, Eisen T, et al. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. Eur Urol. 2018. PMID: 29784193. doi:10.1016/j.eururo.2018.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。